Drug intelligence / Profile preview

D2 dopamine program

Development stage: Preclinical
Lead developer: ConfometRx
Modality: Small Molecules

Overview

The D2 dopamine program is a drug discovery initiative by ConfometRx targeting the D2 dopamine receptor for the treatment of psychiatric disorders. Utilizing a small molecule modality, the program is currently in the lead generation phase of development. ConfometRx employs structural biology and GPCR-specific platforms to identify candidates that can precisely modulate D2 receptor signaling, although the specific functional profile (e.g., agonist vs. antagonist) has not been disclosed. This program represents part of the company's broader pipeline of GPCR-targeted therapies for CNS and metabolic conditions.

Other names: D2 dopamine receptor programD-2 dopamine receptor programD 2 dopamine receptor program

Targets

DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on D2 dopamine program.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D2 dopamine program.

Explore the full profile